Zakim Practice Manager
About the job
- Working knowledge of computers is required.
- Previous experience with the Epic electronic medical record system is preferred.
- Strong verbal and written communication, conflict resolution, and interpersonal skills are required.
- Demonstrated organizational, critical-thinking, analytic, and decision-making skills are required.
- Ability to work effectively as a member of an interdisciplinary team is required.
- Ability to establish rapport with patients and families from diverse cultural, ethnic, and religious backgrounds is required.
- Flexibility to set and change priorities, accept additional responsibilities as situations require, and respond positively to new approaches and workplace changes is required.
- A bachelor's degree in Healthcare Administration, Business Administration, or a related field is required.
- Five years of progressively responsible ambulatory care management or similar clinical care experience is required.
- Previous experience managing staff is preferred.
- Provide oversight of daily patient experience and clinic operations for the Zakim Center, partnering with the Clinic Medical Director and Administrative Director on strategic initiatives and quality-improvement projects.
- Collaborate with clinical and administrative leaders to identify operational issues, recommend solutions, and support continuous improvement while ensuring operations align with organizational goals, service standards, and patient-care priorities.
- Manage day-to-day scheduling for Zakim services across the Longwood campus and regional locations; monitor reports, identify gaps, and resolve issues in complex scheduling systems.
- Create, edit, and modify provider and nursing templates in Epic according to leadership and clinician needs.
- Establish and maintain scheduling best practices across departments and services to ensure compliance with Institute standards and support the Zakim care model.
- Assist in developing documentation, referral pathways, and operational workflows for new service lines; collaborate with research and Epic teams on study-participant scheduling, system updates, efficiency improvements, and adoption of new tools.
- Monitor provider-template utilization with the Disease Center Administrative Director and recommend improvements to maximize exam-room use, room efficiency, and clinic flow.
- Oversee patient rooming, movement, and real-time throughput to ensure visits are safe, efficient, and patient-centered; make operational adjustments to minimize delays and maintain clinic flow.
- Ensure infection-control practices comply with institutional standards and infection-control department guidance.
- Manage patient feedback and complaints, including matters filed through Patient Family Relations, and work with staff, patients, and leadership to resolve concerns promptly and professionally.
- Implement corrective actions and process improvements to enhance patient experience, and proactively identify service issues and barriers to care with clinicians, staff, and leadership.
- Promote a responsive, respectful, and supportive environment for patients and families.
- Forecast, develop, monitor, and evaluate the clinical-floor annual budget, including variance analysis and improvement plans.
- Oversee the Zakim Center financial-assistance program, including tracking and administering patient-support funds.
- Manage clinic payment collection, including online payments, credit-card processing, and care-card usage; collaborate with Patient Accounting to review, reconcile, and ensure accuracy of charges, payments, and related financial records.
- Ensure compliance with organizational policies, procedures, and applicable requirements, including HIPAA, Department of Public Health standards, CMS, and The Joint Commission.
- Serve as the clinic's first point of contact for IT equipment and user-interface issues; support troubleshooting and communication during technology outages to minimize disruption to patient care.
- Provide administrative support during medical emergencies and lead or coordinate staff and patients during emergency-response events.
- Participate in contingency planning for weather-related or other unplanned disruptions, and coordinate with Facilities on repairs, maintenance, and environment-of-care issues.
- Supervise Practice Coordinator I, II, and Lead staff (four FTEs), and provide direct or indirect supervision of practitioner staff, including massage therapists and acupuncturists.
- Hire, develop, and manage staff; set expectations, deliver feedback, monitor performance for quality, efficiency, and policy compliance, mentor staff, foster career growth, and cultivate a positive and productive work environment.
- Interact with patients receiving services in the Zakim Center.
About the company
Dana-Farber Cancer Institute provides cancer treatment and research services in Boston, serving both adult and pediatric patients. It combines patient care with a broad program of clinical trials and basic, translational, and collaborative research to advance cancer treatments. Treatments include personalized care and access to more than 700 clinical trials, aiming to tailor therapies to the patient’s tumor profile and disease type, often through targeted therapies, immunotherapy, chemotherapy, radiation, and surgical options offered at multiple treatment centers and satellite sites. The Institute differentiates itself through its affiliation with Harvard Medical School and Brigham and Women’s Hospital, its long history of cancer research breakthroughs, nationwide and international reach, and the Jimmy Fund to support patients and research. Its goal is to defeat cancer by delivering expert care while rapidly translating research discoveries into new treatments for patients everywhere.
Company Size
5,001-10,000
Company Stage
Grant
Total Funding
$54.9M
Headquarters
Boston, Massachusetts
Founded
1947
Get referred to Dana-Farber Cancer Institute
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 14, 2026 DESTINY-Lung04 strengthened Dana-Farber's lung cancer leadership with first-line T-DXd.
- August 26, 2026 FDA approved Dana-Farber-led daraxonrasib, validating its pancreatic cancer pipeline.
- August 10, 2026 HCMI released nearly 700 patient-derived models for global drug discovery.
What critics are saying
- Mass General Brigham removes Dana-Farber from Medicare Advantage network October 1, 2026.
- Brigham will phase out Dana-Farber physician assistants by December 2026, disrupting inpatient oncology coverage.
- December 2025 DOJ settlement for manipulated NIH grant papers exposes existential compliance damage.
What makes Dana-Farber Cancer Institute unique
- Dana-Farber converts trials into FDA approvals, as daraxonrasib and PATINA showed in 2026.
- Its 300-bed BIDMC hospital, opening 2031, creates a dedicated oncology campus.
- Dana-Farber anchors Harvard-linked research, with 700 clinical trials and world-class disease centers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 16%1 year growth
↑ 16%2 year growth
↑ 16%Modern blood cancer care demands more than a diagnostic result.As patients live longer and therapies become increasingly personalized, physicians need continuous insight into disease biology, immune response, and treatment effectiveness.
Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan improves progression-free survival in her2-mutant NSCLC. Posted date September 14, 2026 A new study led by researchers at Dana-Farber Cancer Institute found that first-line trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC). The findings suggest T-DXd could become a new first-line treatment option for this patient population. The results were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in SEOUL, Republic of Korea on Sept. 14, 2026, by Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology and director of clinical research in thoracic oncology at Dana-Farber. DESTINY-Lung04 is the first global randomized phase 3 trial to show that a HER2-directed therapy can outperform standard first-line chemoimmunotherapy in patients with HER2-mutant NSCLC. In the trial, median progression-free survival by blinded independent central review was 14.3 months with T-DXd, compared with 8.3 months with pembrolizumab plus chemotherapy, representing a 37% reduction in the risk of progression or death. "DESTINY-Lung04 is the first phase 3 trial to demonstrate the benefit of a HER2-directed therapy vs global standard of care as upfront treatment for patients with HER2-mutant NSCLC," said Rotow. The study enrolled 454 previously untreated patients with unresectable locally advanced or metastatic nonsquamous NSCLC harboring HER2 exon 19 or exon 20 mutations. Patients were randomly assigned to receive either single-agent T-DXd every three weeks or pembrolizumab plus platinum chemotherapy and pemetrexed. T-DXd also produced higher response rates than pembrolizumab plus chemotherapy. The objective response rate was 70.0% with T-DXd versus 44.5% with standard treatment, and median duration of response was 13.4 months versus 9.7 months. "These results demonstrate substantial improvements in progression-free survival and response with first-line trastuzumab deruxtecan for patients with advanced or metastatic HER2-mutant NSCLC," said Rotow. "The findings support T-DXd as a new first-line treatment option for this patient population, for whom more effective HER2-directed approaches are needed." Median overall survival was 29.3 months with T-DXd and 33.1 months with pembrolizumab plus chemotherapy, though investigators noted that differences in subsequent therapies between the groups complicated interpretation. The DESTINY-Lung04 findings support first-line T-DXd as an important new treatment option for patients with HER2-mutant NSCLC. Lung Cancers Lung Cancer, non-small cell Related Doctors and Researchers Media Contacts If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email [email protected]. The Media Team cannot respond to patient inquiries. For more information, please see Contact Us. Julia Rotow, MD
Command palette. 5 hours ago Researchers from St. Jude Children's Research Hospital, the University of Pavia, Dana-Farber Cancer Institute, and Harvard Medical School have unveiled AdaptiveFlow, an open-source artificial intelligence platform engineered to transform ultra-large-scale virtual drug screening. Published this week in Nature Biotechnology, the framework eliminates longstanding computational bottlenecks by enabling the routine examination of billions of drug-like molecules while cutting processing costs by a factor of one thousand compared to conventional methods. The platform achieves unprecedented scalability through an architecture that maintains linear performance efficiency across up to 5.6 million virtual central processing units. This design circumvents the communication overhead that typically degrades high-performance computing systems as processor counts rise. AdaptiveFlow centers on an eighteen-dimensional computational grid, with each axis encoding a specific molecular characteristic. This multidimensional mapping allows automated prioritization of chemically diverse candidates, which are filtered through a machine-learning classifier trained on prescreening outputs. The system integrates more than fifteen hundred molecular docking protocols to evaluate and rank compounds based on predicted target binding affinity. To demonstrate practical utility, the development team executed a virtual screen of sixty-nine billion molecules, establishing the largest ready-to-dock library utilized in a single discovery campaign. AdaptiveFlow successfully isolated high-affinity inhibitors for poly(ADP-ribose) polymerase 1, a validated oncology target, and ferroptosis suppressor protein 1, an emerging target implicated in cancer cell survival. The successful targeting of FSP1, which features a structurally complex binding pocket containing an additional cofactor, confirms the platform's capability to navigate challenging pharmacological environments. Initial candidate quality from AdaptiveFlow consistently surpassed traditional screening outputs, substantially shortening the lead optimization timeline. By merging advanced machine learning with massively parallel cloud infrastructure, the platform democratizes access to comprehensive chemical space exploration. The creators emphasize that removing cost and technical barriers will accelerate therapeutic pipeline development, particularly for historically intractable biological targets. The entire framework, along with implementation documentation and usage tutorials, is available free of charge on GitHub and the official project repository. AdaptiveFlow marks a definitive transition toward scalable, economically viable computational drug discovery, enabling research institutions to systematically convert massive chemical datasets into clinically viable therapeutics. This news is intelligently aggregated by AI to deliver industry updates efficiently. It does not constitute opinions or advice.
PICI invests more than $1 million in five Early Career researchers advancing the future of Cancer Immunotherapy. PICI has now awarded more than $23.9 million total to fund 63 research projects in the last decade, powering the next generation of cancer immunotherapies SAN FRANCISCO - August 19, 2026 - The Parker Institute for Cancer Immunotherapy (PICI) today announced its 2026 class of Early Career Researcher awardees. The five investigators selected this year will receive more than $1 million in combined funding to advance innovative research projects that leverage cutting-edge scientific approaches that will accelerate the development of next-generation immunotherapies for cancer patients. Now in its tenth year, PICI's Early Career Researcher Awards program has invested $23.9 million across 63 research projects. Beyond funding, the program provides promising scientists with access to PICI's collaborative research network and world-class scientific resources, empowering them to pursue bold, high-risk, high-reward ideas that have the potential to transform cancer treatment. "Some of the most transformative advances in cancer research begin with scientists willing to ask difficult questions and pursue ideas that challenge conventional thinking," said Dr. Karen Knudsen, CEO of PICI. "The Early Career Researcher Awards give these emerging leaders the resources, community and support to take their ideas further. We're excited to invest in this exceptional group of scientists and in the discoveries they may bring to patients." Four of this year's awardees are Parker Scholars, early career scientists entering their first postdoctoral appointment in a high-impact area of cancer immunotherapy. PICI has also recognized one Parker Bridge Fellow, an investigator who recently completed their MD or PhD and is ready to establish a laboratory or independent program in cancer immunotherapy. * Parker Scholar Sophie Louise Gray-Gaillard of the University of Pennsylvania is investigating how the spatial organization of the tumor microenvironment shapes tumor-infiltrating CD8 T lymphocyte function. Ms. Gray-Gaillard will study the cellular interactions and molecular signals that distinguish tumor-specific T cells from nontumor-specific "bystander" T cells, to inform more precise immunotherapeutic strategies for cancer patients. * Parker Scholar Jingya Qiu, PhD, of Gladstone Institutes is investigating how immune responses within tissue microenvironments contribute to cancer initiation. Dr. Qiu will use spatiotemporal imaging and digital pathology to understand how premalignant tissues interact with the immune system, with the goal of developing immune-based strategies for early cancer detection and intervention before cancer progresses to invasive disease. * Parker Scholar Xinyu Xiang of Stanford Medicine is developing a new platform to generate T cell receptor mimetics that can recognize tumor-associated peptide-MHC complexes with high specificity. Ms. Xiang will integrate protein engineering, synthetic co-evolution, and machine learning to systematically discover new binders and expand the range of cancer targets that can be recognized by targeted immunotherapies. * Parker Scholar Shaobo Yang, PhD, of Dana-Farber Cancer Institute is developing programmable bacterial "living medicines" for solid tumors. Dr. Yang will advance the Living Immune Modulating Engager (LIME) platform, using tumor-homing bacteria to connect cancer cells with T cells or natural killer cells directly within tumors and enhance responses to RAS-targeted therapy. * Parker Bridge Fellow Maxime Meylan, PhD, of Dana-Farber Cancer Institute is investigating how the organization of the tumor microenvironment shapes T-cell responses in cancer. Dr. Meylan will study how tumor cell states and spatial tissue organization create barriers to T-cell infiltration in triple-negative breast cancer, to identify strategies to overcome immune exclusion. Since 2016, PICI's Early Career Researcher program has awarded scientists from a highly competitive field of applicants across PICI's network of leading cancer research centers. Awardees are selected based on their project's proposed scientific approach, the potential impact it will have on the field of cancer immunotherapy, and its alignment with PICI's mission to develop and accelerate access to breakthrough cancer therapies in order to turn all cancers into curable diseases.
Sonal Gandhi joins Dana-Farber as Senior Vice President for Campus Operations and Infrastructure. Posted date August 19, 2026 Dana-Farber Cancer Institute announced today that Sonal Gandhi has been hired as Senior Vice President (SVP) of Campus Operations and Infrastructure, effective August 31. In this role, Gandhi will be responsible for a broad portfolio which includes strategic oversight and excellence of facilities operations, capital construction, real estate, public safety, emergency management, employee services and operational business affairs at Dana-Farber. Additionally, Gandhi will ensure the organization's physical infrastructure, safety programs, and operational services to support the growth and long-term sustainability for the Institute. Prior to joining Dana-Farber, Gandhi served as Vice President, Real Estate, Planning and Construction for Brigham and Women's Hospital (BWH) and Faulkner Hospital. In this role, she led real estate strategy and capital planning across both facilities, including leading BWH's long-term transformation strategy for incremental inpatient capacity, research, ambulatory and administrative space optimization. "Sonal brings extensive experience leading real estate strategy, capital planning and organizational transformation across academic medicine, healthcare systems and government," said William C. Hahn, MD, PhD, Executive Vice President and Chief Operating and Transformation Officer at Dana-Farber. "We are fortunate to have the benefit of her experience, expertise and talent as we continue to advance Dana-Farber's bold vision for the future of cancer care." Gandhi spent 20 years at the Boston Planning & Development Agency in roles of increasing responsibility, where she led major economic development and intergovernmental initiatives across housing, workforce, climate and institutional growth priorities. Throughout her career, she has built strong partnerships across executive leadership, regulatory agencies and diverse stakeholders to advance bold growth visions and complex initiatives. Gandhi holds a bachelor's degree in architecture from the University of Oklahoma, a master's in urban planning from the Harvard Graduate School of Design, and is a graduate of the Advanced Management Program at Harvard Business School. Media Contacts If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email [email protected]. The Media Team cannot respond to patient inquiries. For more information, please see Contact Us. Sonal Gandhi